The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone
Open accessAbstract
During development, growth factors and hormones cooperate to establish the unique sizes, shapes and material properties of individual bones. Among these, TGF-beta has been shown to developmentally regulate bone mass and bone matrix properties. However, the mechanisms that control postnatal skeletal integrity in a dynamic biological and mechanical environment are distinct from those that regulate bone development. In addition, despite advances in understanding the roles of TGF-beta signaling in osteoblasts and osteoclasts, the net effects of altered postnatal TGF-beta signaling on bone remain unclear. To examine the role of TGF-beta in the maintenance of the postnatal skeleton, we evaluated the effects of pharmacological inhibition of the TGF-beta type I receptor (TbetaRI) kinase on bone mass, architecture and material properties. Inhibition of TbetaRI function increased bone mass and multiple aspects of bone quality, including trabecular bone architecture and macro-mechanical behavior of vertebral bone. TbetaRI inhibitors achieved these effects by increasing osteoblast differentiation and bone formation, while reducing osteoclast differentiation and bone resorption. Furthermore, they induced the expression of Runx2 and EphB4, which promote osteoblast differentiation, and ephrinB2, which antagonizes osteoclast differentiation. Through these anabolic and anti-catabolic effects, TbetaRI inhibitors coordinate changes in multiple bone parameters, including bone mass, architecture, matrix mineral concentration and material properties, that collectively increase bone fracture resistance. Therefore, TbetaRI inhibitors may be effective in treating conditions of skeletal fragility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Transforming Growth Factor-β1 to the Bone
Janssens, K., ten Dijke, P., Janssens, S., & Van Hul, W. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0001 · Cited by 710
Karst, M., Gorny, G., Galvin, R. J. S., & Oursler, M. J. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20036 · Cited by 184 · cited 2×
“TGF-b also regulates osteoblast expression of osteoclast regulatory factors m-CSF, RANKL, and OPG [23–25], whereas resorbing osteoclasts release and activate matrix-bound latent TGF-b, which feeds back to modulate osteoblast and osteoclast function [26–28].”
BackgroundOsteoclast synthesis and secretion and activation of latent transforming growth factor β
Oursler, M. J. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090402 · Cited by 153
Suva, L. J., Hartman, E., Dilley, J. D., Russell, S., Akel, N. S., Skinner, R. A., Hogue, W. R., Budde, U., Varughese, K. I., Kanaji, T., et al. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070417 · Cited by 75
Self-citation
Cited by
Cancer to bone: a fatal attraction
Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3055 · Cited by 1,285
Self-citationBone metastasis: mechanisms and therapeutic opportunities
Suva, L. J., Washam, C., Nicholas, R. W., & Griffin, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.227 · Cited by 424
Self-citationExcess TGF-β mediates muscle weakness associated with bone metastases in mice
Waning, D. L., Mohammad, K. S., Reiken, S., Xie, W., Andersson, D. C., John, S., Chiechi, A., Wright, L. E., Umanskaya, A., Niewolna, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3961 · Cited by 378
Self-citationChen, J.-H., & Simmons, C. A. (2011) · Circulation Research · doi:10.1161/circresaha.110.234237 · Cited by 289
Dunn, L. K., Mohammad, K. S., Fournier, P. G. J., McKenna, C. R., Davis, H. W., Niewolna, M., Peng, X. H., Chirgwin, J. M., & Guise, T. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006896 · Cited by 212
Self-citation
Metadata
- Authors
- Mohammad, K. S., Chen, C. G., Balooch, G., Stebbins, E., McKenna, C. R., Davis, H., Niewolna, M., Peng, X. H., Nguyen, D. H. N., Ionova-Martin, S. S., Bracey, J. W., Hogue, W. R., Wong, D. H., Ritchie, R. O., Suva, L. J., Derynck, R., Guise, T. A., & Alliston, T.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-04-16
- Volume
- 4
- Issue
- 4
- Pages
- e5275
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1975522291
- Cited by
- 179
- References
- 6
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone. https://app.cochat.ai/papers/10.1371/journal.pone.0005275
- The paper
- Mohammad, K. S., Chen, C. G., Balooch, G., Stebbins, E., McKenna, C. R., Davis, H., Niewolna, M., Peng, X. H., Nguyen, D. H. N., Ionova-Martin, S. S., Bracey, J. W., Hogue, W. R., Wong, D. H., Ritchie, R. O., Suva, L. J., Derynck, R., Guise, T. A., & Alliston, T. (2009). Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on Bone. PLoS ONE. https://doi.org/10.1371/journal.pone.0005275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.